BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Hong Kong

GenEditBio Secures US FDA IND Clearance For First In Vivo Genome Editing Trial In TGFBI Corneal Dystrophy

GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. F...

January 06, 2026 | News

Ascletis Secures US FDA IND Clearance For Phase II Diabetes Study Of Oral GLP One Candidate ASC30

-The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the effi...

January 06, 2026 | News

Sisram Medical Clears Final Regulatory Step For DAXXIFY Market Entry In China

Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio Sisram Medical Ltd (the "Company...

January 06, 2026 | News

Insilico Medicine Signals The Arrival Of AI First Drug Development With HKD 2.27 Billion IPO

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully lis...

December 31, 2025 | News

HKSH Medical Group And Shenzhen Cancer Hospital Formalise Proton Therapy Collaboration Under Healthy China 2030 Framework

In alignment with the national framework for the advancement of proton therapy, facilitated by the National Cancer Center, HKSH Medical Group ("HKSH")...

December 25, 2025 | News

Peijia Medical Secures China Regulatory Approval For TaurusTrio Transcatheter Aortic Valve System

Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, a...

December 16, 2025 | News

Akeso Secures FDA Clearance to Launch Global Phase III Gastric Cancer Trial of Cadonilimab

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in ...

December 15, 2025 | News

Lee’s Pharm Acquires Staccato One Breath Technology Platform to Strengthen Global Inhalation Drug Pipeline

Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential Synergistic and complementar...

December 11, 2025 | News

Antengene Secures Expanded Approvals For Xpovio In Hong Kong Across Multiple Myeloma And DLBCL

- XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for mul...

December 04, 2025 | News

Antengene Secures NMPA Approval for IND of CLINCH Two Combination Study in Gastric Cancer

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...

December 03, 2025 | News

Ascletis Advances First Oral Triple Agonist for Obesity, ASC37, into Clinical Development

- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability ...

December 01, 2025 | News

IASO Bio Achieves Landmark Hong Kong Approval for Fucaso CAR-T Therapy

IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commerciali...

November 28, 2025 | Regulatory

ToolGen and GenEditBio Join Forces to Advance Next Generation In Vivo Genome Editing

Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-...

November 25, 2025 | News

Akeso Receives NMPA Clearance to Initiate Clinical Trials for China’s First Bispecific Antibody for Alzheimer’s Disease

Akeso, Inc. (HKEX: 9926.HK) announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aβ) and blood-brain barrier (BBB) expre...

November 18, 2025 | News

Stay Connected